TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06466486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin delta
Description: The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin delta
Description: The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin delta
Description: The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
Study: NCT05876572

Intervention type: DRUG
Group type: OTHER
Intervention: intradermal naloxone
Description: One time 8 mg/0.1 mL dose of naloxone to be administered intradermally

Intervention type: DEVICE
Group type: OTHER
Intervention: microneedle injection
Description: Intradermal delivery of naloxone using microneedle
Study: NCT06469658

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The standard practice dietary supplements intervention
Description: Participants receive supplements prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The AI-guided practice dietary supplements group
Description: Participants receive DS prescriptions determined by GenAIS, an AI system which considers genetic data, metabolic profiles, biochemical markers, and patient history.
Study: NCT04778761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home ACP Video
Description: A video focused on Advance Care Planning and Hospice for patients with serious illness
Study: NCT06387238

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA PET/CT
Description: pre-therapeutic PSMA PET/CT and post-therapeutic PSMA PET/CT after three-month novel endocrine therapy.
Study: NCT06050512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib, a second-generation proteasome inhibitor, is used primarily in the treatment of multiple myeloma. This activity outlines the mechanism of action, indications, and contraindications for ixazomib as a valuable agent for treating multiple myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib, a second-generation proteasome inhibitor, is used primarily in the treatment of multiple myeloma. This activity outlines the mechanism of action, indications, and contraindications for ixazomib as a valuable agent for treating multiple myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Corticosteroids, such as dexamethasone and prednisone, are an important part of the treatment of multiple myeloma. They can be used alone or combined with other drugs as a part of treatment. Corticosteroids are also used to help decrease the nausea and vomiting that chemo might cause.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Corticosteroids, such as dexamethasone and prednisone, are an important part of the treatment of multiple myeloma. They can be used alone or combined with other drugs as a part of treatment. Corticosteroids are also used to help decrease the nausea and vomiting that chemo might cause.
Study: NCT05522114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMJ injection using patient specific guide
Description: Prefabricated patient specific guide used to guide the needle into the superior joint space of TMJ while real time MSCT evaluate the accuracy of needle position. Sodium hyaloronate injected within the superior joint space.
Study: NCT04880057

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance+Aerobic training
Description: The RT focuses on lower extremity workout, including leg press, hamstring curls, and calf raises. The participants start with intensity at 12 RM and finished with intensity at 8 RM after 3 weeks. There are 8 repetitions, 2 sets for each action. It will take 15 minutes to complete RT.~The AeT is composed by cycling on stationary bikes in the first week, stepping on steppers in 2nd week, and running on treadmills in the last week. Participants are asked to wear a portable heart rate monitor throughout the experiments. They have to maintain their heart rates in 60%-75% of predicted maximal heart rate (moderate intensity exercise), which has been shown to be benefit on cognition\[3\]. It took the participants 25 minutes to complete AeT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agility training
Description: AT program consists of three parts: technical drills, pattern running and reactive agility training. There will be nine sessions over 3 weeks and progress the intensity, complexity or velocity every week.
Study: NCT04962165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device
Description: The device maintain opened upper airway by moving the lower jaw slightly forward while sleeping.
Study: NCT05940246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: MI was introduced by William Miller in 1983 as a strategy to promote behavioral changes that would make people drink less. It is well established that MI can be successfully applied to many areas across the medical disciplines. Although the aim of MI is behavioral changes toward a specific goal it is necessary to understand the essence of MI with the four key interrelated elements of the spirits of MI. These are partnership, acceptance, compassion, and evocation. Together they form an equal and respectful collaboration between the MI practitioner and the patient wherein empathy and acknowledgment are important pillars. Moreover, an important message derived from the spirit of MI is the belief that patients in themselves have and know what is needed and get support from the MI practitioner to find it.
Study: NCT06535646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program using Physitrack exercise program and a smart watch
Description: Participants wear a smart watch to monitor activity levels while using a web based exercise program to follow along for 8 weeks.
Study: NCT06315894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SuperCAP Program
Description: Distance program including tasks and exercises to improve cognitive, emotional, and functional status.~The intervention will be applied via cell phone and will have a duration of 3 months (12 weeks).~Tasks and exercises will be performed 5 days per week. Contents of the program will include daily exercises, daily games, daily videos, and weekly videos.~They will address cognitive functions, daily habits, and lifestyle factors in general.~Compliance will be monitored to control the adherence to the intervention. The program has been designed specifically for people with post-COVID syndrome.
Study: NCT05837312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reconnecting to Internal Sensations and Experiences
Description: Reconnecting to Internal Sensations and Experiences (RISE) is a novel, self-guided interoceptive intervention designed to be accessible and convenient. RISE is hosted on Qualtrics and accessed on any internet-enabled device. RISE consists of four interactive 30-minute modules: (1) Progressive Muscle Relaxation and Body Functionality, (2) Understanding, Noticing and Managing Emotions, (3) Self-care and Communication, and (4) Body Sensations. The training consists of a mix of audio clips, psychoeducation, self-guided reading, and interactive writing prompts. Intervention materials are separated by multiple free-response prompts so that participants can relate the materials to their own lives, practice the introduced skills, and problem-solve difficulties implementing the skills.
Study: NCT06466486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin delta
Description: The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Follitropin delta
Description: The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Follitropin delta
Description: The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FE999302
Description: To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FE999302
Description: To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FE999302
Description: To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FE999302
Description: To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FE999302 Placebo
Description: To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FE999302 Placebo
Description: To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FE999302 Placebo
Description: To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
Study: NCT04265768

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue augmentation surgery with CTG
Description: An epithelial-connective tissue graft of approximately 2-3 mm of thickness and adequate length will be taken from the palate or retromolar region of the patient and de-epithelialized with a scalpel (ideally a thickness of 1.5-2.0mm).~The connective tissue graft (CTG) obtained will then be positioned buccally to the dental implant and sutured to the internal side of the flap so to provide soft tissue bulk at the level of the neck of the implant and simulate a root prominence for the missing tooth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue augmentation surgery with Fibro-Gide
Description: Fibro-Gide will be used to obtain buccal soft tissue augmentation. Fibro-Gide will be trimmed with a scalpel and adjusted in size and thickness to better adapt to the area buccal to the implant. In particular, the graft will be shaped in order to obtain a graft of approximately 2-3 mm of thickness and adequate length. Fibro-Gide will then be sutured to the inner side of the buccal flap, before repositioning the flap and suturing it in a tension-free way.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No soft tissue augmentation
Description: During implant placement surgery, no soft tissue augmentation will be performed
Study: NCT06290245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEP Buddy
Description: It is a hands-free, oral PEP device (PEP buddy) which held by the patient's lips like a whistle and is attached to a necklace/lanyard. Different grades of PEP-buddy generate expiratory pressures of 5-17cm H2O

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: Exercise training will start and finish with a 5-minute warm-up and cool-down on the cycle ergometers at (40% of PHR). The cycling active phase will last for 30 min. at 70% of HRmax (moderate-intensity continuous exercise).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Exercise training will start and finish with a 5-minute warm-up and cool-down on the cycle ergometers at (40% of PHR). The cycling active phase will last for 30 min. at 70% of HRmax (moderate-intensity continuous exercise).
Study: NCT05509894

Intervention type: DRUG
Intervention: Ngenla
Description: As provided in real world practice
Study: NCT06311227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT04735185

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous stem cells
Description: In this intervention participants will receive a 2 mL intradiscal injection into each affected disc of autologous bone marrow-derived mesenchymal stem cells from bone marrow aspirate of the posterior ilium.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: In this intervention participants will receive a 1 mL intradiscal injection of the steroid methylprednisolone (40 mg/mL) into each affected disc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic
Description: In this intervention participants will receive a 1 mL intradiscal injection of the local anesthetic bupivacaine 0.5% into each affected disc.
Study: NCT06443281

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurophysiology
Description: Pain-related evoked potentials and nerve conduction studies
Study: NCT06311227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06443281

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurophysiology
Description: Pain-related evoked potentials and nerve conduction studies

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurophysiology
Description: Pain-related evoked potentials and nerve conduction studies

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurophysiology
Description: Pain-related evoked potentials and nerve conduction studies

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular test
Description: Blood pressure control, orthostatic intolerance test, baro-reflex sensitivity, heart-rate variability

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular test
Description: Blood pressure control, orthostatic intolerance test, baro-reflex sensitivity, heart-rate variability

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular test
Description: Blood pressure control, orthostatic intolerance test, baro-reflex sensitivity, heart-rate variability

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular test
Description: Blood pressure control, orthostatic intolerance test, baro-reflex sensitivity, heart-rate variability

Intervention type: DIAGNOSTIC_TEST
Intervention: Experimental pain paradigms
Description: Temporal summation of pain, conditioned pain modulation

Intervention type: DIAGNOSTIC_TEST
Intervention: Experimental pain paradigms
Description: Temporal summation of pain, conditioned pain modulation
Study: NCT06565936

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG
Description: Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.

Intervention type: RADIATION
Group type: OTHER
Intervention: PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG
Description: Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG
Description: Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.
Study: NCT06311227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06364072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT001
Description: Intranasal
Study: NCT06552299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laypersons
Description: 1. Participants will be asked to draw a 5cm line.~2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health-Care Providers
Description: 1. Participants will be asked to draw a 5cm line.~2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance.
Study: NCT06181435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:~Injection solution Route of administration: SC injection
Study: NCT06364631

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion. Nivolumab is to be administered first. The nivolumab infusion must be promptly followed by a saline flush to clear the line of nivolumab before starting the ipilimumab infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion. Nivolumab is to be administered first. The nivolumab infusion must be promptly followed by a saline flush to clear the line of nivolumab before starting the ipilimumab infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Ipilimumab
Description: The second infusion will always be ipilimumab and will start at least 30 minutes after completion of the nivolumab infusion. Ipilimumab is to be administered as an approximately 30-minute IV infusion.~When administered together, nivolumab and ipilimumab will be administered on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab is to be administered as an approximately 30-minute IV infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Cabozantinib
Description: Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.

Intervention type: DRUG
Group type: OTHER
Intervention: Axitinib
Description: Axitinib is a medication that is taken orally every day, 2 times a day continuously, at the starting dose of 5mg x2/day.

Intervention type: DRUG
Group type: OTHER
Intervention: Lenvatinib
Description: Lenvatinib is a medication that is taken orally every day, once a day at the initial dose of 20mg/day.
Study: NCT05388708

Intervention type: DEVICE
Intervention: ECMO support
Description: ECMO prescribed by treating physicians for respiratory support in the setting of PARDS.

Intervention type: OTHER
Intervention: PROSpect protocolized therapies
Description: PROSpect is testing the impact of supine/prone positioning and conventional mechanical ventilation (CMV)/high-frequency oscillatory ventilation (HFOV) on clinical outcomes in 1,000 children with severe PARDS. PROSpect manages severe PARDS subjects using a protocol that reserves ECMO for protocol failure.~The CMV group targets an exhaled tidal volume of 5-7mL/kg of ideal body weight and a peak inspiratory pressure \<28 cm of H2O. The positive end expiratory pressure (PEEP) and FiO2 are titrated by a PEEP-FiO2 titration grid. The HFOV group titrates the mean airway pressure to target a FiO2 \< 0.5 and a goal hemoglobin oxygen saturation of 88-92%. The frequency is titrated between 8-12 Hz and amplitude from 60-90 to achieve a goal pH of 7.15-7.30. Ventilation protocols are implemented until 28 days or extubation. Children randomized to the prone positioning will remain prone for at least 16 consecutive hours per day. Children randomized to supine positioning group remain supine.
Study: NCT04251377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defensive Antiadhesive Coating DAC®, Novagenit SRL
Description: DAC gel, mixed with topical antibiotics is applied on the surface of the implants before implantation, in a sterile environment in the operating room.~The topical antibiotics will be added to the reconstituted DAC® gel preparation, at the discretion of the physician, on the basis of pre-operative culture.
Study: NCT05748782

Intervention type: OTHER
Intervention: Baska Mask
Description: The Baska mask (Logikal Health Products PTY Ltd., Morisset, NSW, Australia) is a supraglottic airway device introduced in 2012 with many innovations that might be expected to overcome these derangements.

Intervention type: DEVICE
Intervention: Endotracheal tube
Description: BASKA Mask